Thus, our results have exhibited the potential value ofKMO in predicting the risk of recurrence and patient survival in subgroups withnormal AFP levels (AFP < 20 ng/ml) or in the early-stage HCC group, whichwould have been difficult using currently clinically available surrogatebiomarkers. Here, AFP is linked to hepatocellular carcinoma.